MiCareo focuses on precise cell analysis for precision medicine, liquid biopsy, and academic research, specializing in rare cells such as CTCs, immune, stem, precursor, and maternal-fetal cells. Our MiCount platform offers a cost-effective, simplified alternative to advanced flow cytometry for low-abundance cell analysis. We excel in microfluidic chip design, system integration, and biotech R&D, supporting clinical diagnostics, personalized healthcare, and biomarker discovery. Our MiSelect R platform enables rapid isolation of single rare cells from whole blood without PBMC isolation or RBC lysis, detecting over 13 biomarkers per cell. It’s been proven in clinical, preclinical, vaccine, and disease studies. MiCareo holds 30+ global patents for its eDAR microfluidic technology. We also partner with Energenesis Biomedical to distribute TopCells™?chemically-defined cell culture reagents?expanding our footprint in cell culture applications.
moreEXHIBIT
CytoMore™ Cell Rescue Supplement (CT01-1BT)
CytoMore™ is a chemically defined supplement designed to enhance cell culture conditions. It demonstrates superior performance in supporting low-viability cells, including primary cells, mesenchymal stem cells (MSCs), and cryopreserved cell lines.
More
HybriMore™ Hybridoma Culture Supplement (#HB01-1L)
HybriMore™ is a chemically defined supplement designed to improve hybridoma survival after cell fusion. It enhances hybridoma growth and screening efficiency under low-serum or serum-free conditions during clone selection and antibody production.
More
NeuronMore™ Neural Cell Culture Supplement (#CT02-1L)
NeuronMore™ is a chemically defined supplement, which is to help culturing of neural cells. It enhances growth, maintains potency and rejuvenates the neuron cells. It also enhances growth of neuron cells under low-serum or serum-free conditions.
More
MiCount Cell Analysis System
MiCount Cell Analyzer by MiCareo is an innovative automated platform that integrates fluorescence detection with microfluidic technology, specifically designed for laboratory use. It provides researchers and clinical laboratories with a cost-effective solution for the detection of low-abundance or low-frequency cells, such as CD34+ stem cells, circulating endothelial cells (CECs), regulatory T cells (Tregs), and CAR-T immune cells.
More
MiSelect R II - Next Generation Cell Analysis Platform
MiCareo revolutionizes liquid biopsy, providing non-invasive disease detection and monitoring. Unlike traditional biopsies, our method is simple, repeatable, and cost-effective. The MiSelect R II System isolates and analyzes circulating tumor cells, immune cells, and EPCs with high sensitivity (10^-7). It enables rare-cell retrieval for genetic analysis, essential for cancer diagnostics and CAR-T therapy. With FDA class II IVD listed and ISO13485, MiCareo ensures accurate, reliable results.
More
COMPANY INTRODUCTION
MiCareo focuses on precise cell analysis for precision medicine, liquid biopsy, and academic research, specializing in rare cells such as CTCs, immune, stem, precursor, and maternal-fetal cells. Our MiCount platform offers a cost-effective, simplified alternative to advanced flow cytometry for low-abundance cell analysis. We excel in microfluidic chip design, system integration, and biotech R&D, supporting clinical diagnostics, personalized healthcare, and biomarker discovery. Our MiSelect R platform enables rapid isolation of single rare cells from whole blood without PBMC isolation or RBC lysis, detecting over 13 biomarkers per cell. It’s been proven in clinical, preclinical, vaccine, and disease studies. MiCareo holds 30+ global patents for its eDAR microfluidic technology. We also partner with Energenesis Biomedical to distribute TopCells™?chemically-defined cell culture reagents?expanding our footprint in cell culture applications.
